Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Bernell

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Hematological Oncology|May 1, 1991
Increase of serum interleukin-2 and regression of myeloma after rhGM-CSF treatment of drug induced bone marrow aplasiaP Bernell, P Pisa, R Hast, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 23, 1998
Addition of etoposide to CHOP chemotherapy in untreated patients with high-grade non-Hodgkin's lymphomaF Celsing, S Widell, K Merk, et al.
Leukemia|September 13, 2003
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative diseaseR Hast, E Hellström-Lindberg, L Ohm, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Hematological Oncology|May 1, 1991
Increase of serum interleukin-2 and regression of myeloma after rhGM-CSF treatment of drug induced bone marrow aplasiaP Bernell, P Pisa, R Hast, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 23, 1998
Addition of etoposide to CHOP chemotherapy in untreated patients with high-grade non-Hodgkin's lymphomaF Celsing, S Widell, K Merk, et al.
Leukemia|September 13, 2003
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative diseaseR Hast, E Hellström-Lindberg, L Ohm, et al.
Pageof 3